Pegylated liposomal doxorubicin in ovarian cancer.

Item

http://www.wikidata.org/entity/Q43065300

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Pegylated liposomal doxorubicin in ovarian cancer.

@en

Pegylated liposomal doxorubicin in ovarian cancer.

@nl

type

Item

label

Pegylated liposomal doxorubicin in ovarian cancer.

@en

Pegylated liposomal doxorubicin in ovarian cancer.

@nl

prefLabel

Pegylated liposomal doxorubicin in ovarian cancer.

@en

Pegylated liposomal doxorubicin in ovarian cancer.

@nl

P1476

Pegylated liposomal doxorubicin in ovarian cancer.

@en

P2093

Daniela Matei

http://www.w3.org/2001/XMLSchema#string

Robert Strother

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Risk factors for doxorubicin-induced congestive heart failure

Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.

Phase II study of liposomal doxorubicin in advanced gynecologic cancers.

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.

A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.

Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.

Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.

P304

639-650

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19707541

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

2731020

http://www.w3.org/2001/XMLSchema#string